article Open AccessTop 1% cited
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
New England Journal of Medicine · 2015 · Vol. 373(17) · pp. 1627–1639
H. Borghaei✉(University Hospital Heidelberg)L. Paz-Ares(Hospital Universitario Virgen del Rocío)Leora Horn(Breast Cancer Research Foundation)David R. Spigel(Sarah Cannon)Martin Steins(University Hospital Heidelberg)Neal Ready(Duke Medical Center)Laura Q.M. Chow(Seattle University)Everett E. Vokes(University of Chicago)Enriqueta Felip(Vall d'Hebron Institute of Oncology)Esther Holgado(Hospital Universitario HM Sanchinarro)Fabrice Barlési(Aix-Marseille Université)M. Kohlhufl(Robert Bosch Hospital)Óscar Arrieta(Instituto Nacional de Cancerología)M. Burgio(Istituti di Ricovero e Cura a Carattere Scientifico)Jérôme Fayette(Centre Léon Bérard)H. Lena(Centre Hospitalier Universitaire de Rennes)Elena Poddubskaya(Russian Cancer Research Center NN Blokhin)David E. Gerber(The University of Texas Southwestern Medical Center)Scott Gettinger(Yale Cancer Center)Charles M. Rudin(Memorial Sloan Kettering Cancer Center)Naiyer A. Rizvi(Memorial Sloan Kettering Cancer Center)L. Crina(Azienda Ospedaliera di Perugia)George R. Blumenschein(Fox Chase Cancer Center)Scott Antonia(Moffitt Cancer Center)Cécile Dorange(Bristol-Myers Squibb (United States))Christopher Harbison(Bristol-Myers Squibb (United States))F. Graf Finckenstein(Bristol-Myers Squibb (United States))Julie R. Brahmer(Sidney Kimmel Comprehensive Cancer Center)
Abstract
Among patients with advanced nonsquamous NSCLC that had progressed during or after platinum-based chemotherapy, overall survival was longer with nivolumab than with docetaxel. (Funded by Bristol-Myers Squibb; CheckMate 057 ClinicalTrials.gov number, NCT01673867.).
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsLung Cancer Research StudiesMedicineDocetaxelNivolumabLung cancerOncologyInternal medicineCancerImmunotherapy
MeSH terms
DocetaxelNivolumabAgedAntibodies, MonoclonalAntineoplastic AgentsCarcinoma, Non-Small-Cell LungFemaleHumansLung NeoplasmsMaleMiddle AgedSurvival AnalysisTaxoidsB7-H1 Antigen
Funding
- Bristol-Myers Squibb
Citations
9,391
FWCI
420.72
field-weighted impact
References
22
Percentile
100%
vs. same field & year
Citations per year
Cited by
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
New England Journal of Medicine · 2018 · 6,460 citations
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
Oncotarget · 2016 · 356 citations
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
The Lancet Oncology · 2016 · 1,385 citations
The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
Clinical Cancer Research · 2016 · 1,045 citations
Oncotarget
Oncotarget · 2016 · 381 citations
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
Cancers · 2020 · 1,166 citations
Recurrent glioma clinical trial, CheckMate-143: the game is not over yet
Oncotarget · 2017 · 415 citations
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
Clinical Cancer Research · 2016 · 1,185 citations
References
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Journal of Clinical Oncology · 2010 · 2,913 citations
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
European Journal of Cancer · 2008 · 28,935 citations
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Science · 2015 · 7,864 citations
The blockade of immune checkpoints in cancer immunotherapy
Nature reviews. Cancer · 2012 · 13,550 citations
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
New England Journal of Medicine · 2010 · 15,037 citations
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
The Lancet Oncology · 2015 · 1,421 citations
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
Journal of Clinical Oncology · 2000 · 2,183 citations
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
Journal of Clinical Oncology · 2004 · 2,425 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.